RESEARCH LIBRARY / THAILAND
Buy Retatrutide in Thailand
Explore Retatrutide (LY3437943), an investigational triple-receptor peptide, with clinical research, laboratory testing information and Thai regulatory considerations.
Research overview · Clinical evidence · Regulatory considerations · Scientific references
Retatrutide strengths, prices and delivery
Delivery across Thailand
Bangkok
Same-day delivery where available.
Nationwide
Typically 1–3 days, depending on destination and dispatch time.
Discreet packaging and delivery updates.
Retatrutide
10 mg: ฿3,000 | 20 mg: ฿4,800 | 30 mg: ฿6,200. Select your preferred strength on the product page.
Retatrutide at a glance
Retatrutide (LY3437943) is an investigational compound developed by Eli Lilly. It acts on three hormone receptors: GIP, GLP-1 and glucagon. It is not an approved treatment and clinical-trial results should not be interpreted as instructions for personal use.
Compound: Retatrutide (LY3437943)
Mechanism: GIP / GLP-1 / glucagon receptor agonism
Development: Clinical investigation
Medical approval: Not approved by the US FDA; verify the latest Thai regulatory position with the Thai FDA.
Mechanism: GIP / GLP-1 / glucagon receptor agonism
Development: Clinical investigation
Medical approval: Not approved by the US FDA; verify the latest Thai regulatory position with the Thai FDA.
What is Retatrutide?
Retatrutide is a synthetic peptide designed to activate three distinct receptors involved in metabolic regulation. The GLP-1 and GIP pathways are also relevant to other incretin-based therapies, while the glucagon receptor adds a third mechanism under investigation.
Three receptors, one investigational molecule
GLP-1: Involved in glucose regulation and appetite signalling.
GIP: An incretin pathway involved in metabolic signalling.
Glucagon: A pathway associated with hepatic glucose regulation and energy metabolism.
GIP: An incretin pathway involved in metabolic signalling.
Glucagon: A pathway associated with hepatic glucose regulation and energy metabolism.
What does clinical research show?
A peer-reviewed Phase 2 randomized trial involving 338 adults with obesity evaluated retatrutide over 48 weeks. The reported mean body-weight change at week 48 was −24.2% in the 12 mg trial group, compared with −2.1% in the placebo group. These are group-level clinical findings, not predictions for individuals.
The trial also documented gastrointestinal adverse events and dose-dependent heart-rate increases. Long-term safety and efficacy continue to require evaluation.
Retatrutide compared with Tirzepatide
Retatrutide: Investigational triple agonist acting on GIP, GLP-1 and glucagon receptors.
Tirzepatide: Dual GIP and GLP-1 receptor agonist, with regulatory approvals in certain countries and indications.
Different studies use different populations, methods and doses. Cross-trial weight-loss percentages should not be treated as a direct head-to-head comparison.
Tirzepatide: Dual GIP and GLP-1 receptor agonist, with regulatory approvals in certain countries and indications.
Different studies use different populations, methods and doses. Cross-trial weight-loss percentages should not be treated as a direct head-to-head comparison.
Regulatory status in Thailand
Retatrutide remains investigational. A label such as “research use only” does not establish that importing, marketing or selling a substance is permitted under Thai law. Before making any regulatory claims, consult current Thai FDA guidance and relevant import and medicines rules.
Understanding purity and batch testing
Independent analytical reports can help researchers assess the identity and reported purity of a particular sample. Look for the batch number, laboratory name, test date, method used, and whether the report matches the actual batch. A purity report alone does not establish sterility, safety, regulatory approval or suitability for human use.
Laboratory storage and handling
Appropriate storage depends on the formulation, packaging, manufacturer specifications and laboratory stability data. Follow validated documentation for the specific material. Do not assume that a general storage claim applies to every batch or preparation.
Frequently asked questions
Is Retatrutide approved in Thailand?
Do not assume approval. Retatrutide is investigational, and current Thai FDA records should be checked for any country-specific authorisation.
What is a triple agonist?
It is a compound designed to activate three different receptors. Retatrutide targets GIP, GLP-1 and glucagon receptors.
Are clinical trial results guaranteed?
No. Published results describe study groups under controlled conditions. They do not guarantee outcomes or establish safety for unregulated products.
Does a certificate of analysis prove a product is safe?
No. A COA documents specific tests on a particular sample. It is not equivalent to regulatory approval or comprehensive safety validation.